Regeneron Stock Plunges. Why a Drug Trial Missed the Mark.
In This Article:
Partners Regeneron and Sanofi say itepekimab only achieved a significantly statistic result in one of two studies.
Oops, something went wrong
Partners Regeneron and Sanofi say itepekimab only achieved a significantly statistic result in one of two studies.